Webb20 jan. 2024 · 4. Discussion. This retrospective cohort study revealed that the use of IABP cannot improve the mortality of AMI-cardiogenic shock patients. Despite the fact that there are still great controversies about the use of IABP that can improve the prognosis of AMI-cardiogenic shock patients and some observational studies revealed a trend toward … Webb18 apr. 2024 · Validation in the IABP-SHOCK II registry population showed good discrimination with an area under the curve of 0.79. External validation in the CardShock trial population (n = 137) showed short-term mortality rates of 28.0% (score 0 to 2), 42.9% (score 3 to 4), and 77.3% (score 5 to 9; p < 0.001) and an area under the curve of 0.73.
Mechanical Support in Early Cardiogenic Shock: What Is the …
Webb5 juli 2024 · 并在IABP-SHOCK Ⅱ试验的163名心源性休克患者中进行验证。. CLIP评分纳入30天死亡率最强预测因子,包括:胱抑素C(Cystatin)、乳酸(Lactate)、白介素 … Webb27 aug. 2012 · Patients Table 1. Table 1. Baseline Characteristics of the Patients. Table 2. Table 2. Clinical Course before Randomization. Between June 16, 2009, and March 3, … country style chicken and fish
2024急性心肌梗死合并心源性休克的诊断与治疗指南解读(完整版)
Webb而影响众多指南对于iabp在stemi治疗中的推荐级别的主要原因在于2012年的iabp-shock Ⅱ研究。 2012年著名的iabp-shockⅡ研究评价了stemi合并cs患者早期血运重建之前或之后使用iabp辅助治疗的疗效以及安全性。该研究包含600例stemi合并cs患者,其中iabp组301例,未行iabp组 ... Webb4 feb. 2024 · Standard severity of illness risk scores perform poorly for predicting mortality in CS patients. 19, 20 Several CS-specific risk tools have been established recently, including scores derived from the IABP-SHOCK II trial and the CardShock study. 18 Utilizing data from the IABP-SHOCK II trial (including only patients with AMI), a 30-day … Webb推荐使用iabp-shock ii评分对心肌梗死合并心源性休克的患者进行风险评估,根据评分将患者分为低、中、高危三组,其30天死亡率分别为20-30% 、40-60%以及70-90%。具体 … brewery\\u0027s ay